6 months | 12 months | Quality-adjusted survival at 12 months | |
---|---|---|---|
Mean EQ5D index (95 % CI) | Mean EQ5D index (95 % CI) | Mean QALY (95 % CI) | |
All patients | 0.5622 (0.5163–0.6081) | 0.5831 (0.5348–0.6314) | 0.2676 (0.2457–0.2894) |
Age | |||
<65 | 0.55 (0.49–0.60) | 0.58 (0.53-0.64) | 0.31 (0.28-0.35) |
≥65 | 0.62 (0.52–0.71) | 0.58 (0.48–0.68) | 0.16 (0.12–0.21) |
Gender | |||
Male | 0.57 (0.51–0.63) | 0.58 (0.52–0.64) | 0.27 (0.23–0.30) |
Female | 0.55 (0.47–0.63) | 0.59 (0.51–0.67) | 0.27 (0.23–0.31) |
APACHE II | |||
<26 | 0.57 (0.52–0.62) | 0.57 (0.52–0.63) | 0.29 (0.26–0.33) |
≥26 | 0.48 (0.34–0.61) | 0.60 (0.50–0.71) | 0.16 (0.12–0.20) |
PaO2:FiO2 ratio (KPa) | |||
<15 | 0.57 (0.51–0.64) | 0.58 (0.51–0.65) | 0.23 (0.20–0.27) |
≥15 | 0.55 (0.48–0.63) | 0.59 (0.52–0.65) | 0.31 (0.27–0.35) |
Ventilation method | |||
Conventional | 0.52 (0.45–0.59) | 0.55 (0.48–0.61) | 0.25 (0.21–0.29) |
HFOV | 0.61 (0.54–0.67) | 0.62 (0.55–0.69) | 0.29 (0.25–0.33) |